Ipsen S.A. (IPN.PA)

120.50 -2.60 (-2.11%) At close: 05:35PM CEST

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 5,325

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David Loew	MD, CEO & Director	2.11M	N/A	1967
Mr. Aymeric Le Chatelier	Executive VP & CFO	731.25k	N/A	1969
Dr. Aidan Murphy Ph.D.	Executive VP and Head of Technical Operations	N/A	N/A	1966
Mr. Craig Marks	Vice-President of Investor Relations	N/A	N/A	N/A
Mr. Francois Garnier	Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer	N/A	N/A	1962
Ms. Gwenan White	Executive VP and Head of Communications, Public Affairs & Sustainability	N/A	N/A	N/A
Mr. Regis Mulot	Executive VP & Chief Human Resources Officer	N/A	N/A	1966
Ms. Dominique Bery	Head of Nordics & Baltics	N/A	N/A	1971
Mr. Bartosz Bednarz D.D.S.	Executive VP and Head of Global Product & Portfolio Strategy	N/A	N/A	N/A
Mr. Philippe Lopes-Fernandes CBO	Executive VP & Chief Business Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Corporate governance

Ipsen S.A.’s ISS governance QualityScore as of 1 June 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.